tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TAK Stock Latest News

Takeda’s Elritercept Trial Targets Transfusion-Dependent MDS: What Investors Should Watch
Company AnnouncementsTakeda’s Elritercept Trial Targets Transfusion-Dependent MDS: What Investors Should Watch
2d ago
TAK
Takeda Advances TAK-861 Into Phase 3 for Narcolepsy With Cataplexy, Setting Up a New CNS Catalyst
PremiumCompany Announcements
Takeda Advances TAK-861 Into Phase 3 for Narcolepsy With Cataplexy, Setting Up a New CNS Catalyst
2d ago
TAK
Takeda’s Mezagitamab Trial Signals Growing Ambition in IgA Nephropathy Market
PremiumCompany Announcements
Takeda’s Mezagitamab Trial Signals Growing Ambition in IgA Nephropathy Market
2d ago
TAK
Takeda announces U.S. availability of Gammagard Liquid ERC
PremiumThe Fly
Takeda announces U.S. availability of Gammagard Liquid ERC
3d ago
TAK
Takeda Targets Chinese Pediatric Market With New Teduglutide Study in Short Bowel Syndrome
PremiumCompany Announcements
Takeda Targets Chinese Pediatric Market With New Teduglutide Study in Short Bowel Syndrome
4d ago
TAK
Takeda’s TAK-411 CIDP Study Progresses: What Investors Should Watch
PremiumCompany AnnouncementsTakeda’s TAK-411 CIDP Study Progresses: What Investors Should Watch
4d ago
TAK
Takeda’s Entyvio Community Trial: What Ongoing Phase 4 Data Could Mean for TAK Investors
Premium
Company Announcements
Takeda’s Entyvio Community Trial: What Ongoing Phase 4 Data Could Mean for TAK Investors
4d ago
TAK
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
9d ago
RR
ENB
Takeda resumed with an Overweight at Morgan Stanley
PremiumThe Fly
Takeda resumed with an Overweight at Morgan Stanley
12d ago
TAK
Leerink views ‘major deal’ on Entyvio as positive for Halozyme
PremiumThe Fly
Leerink views ‘major deal’ on Entyvio as positive for Halozyme
17d ago
TAK
HALO
Halozyme announces global collaboration, license agreement with Takeda
PremiumThe Fly
Halozyme announces global collaboration, license agreement with Takeda
17d ago
TAK
HALO
Alumis price target raised to $32 from $18 at Guggenheim
PremiumThe Fly
Alumis price target raised to $32 from $18 at Guggenheim
18d ago
TAK
ALMS
Takeda, Protagonist Therapeutics submit rusfertide new drug application to FDA
PremiumThe FlyTakeda, Protagonist Therapeutics submit rusfertide new drug application to FDA
20d ago
TAK
PTGX
H.C. Wainwright remains bullish on Xoma following creative Takeda deal
Premium
The Fly
H.C. Wainwright remains bullish on Xoma following creative Takeda deal
26d ago
TAK
XOMA
Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement
Premium
The Fly
Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement
26d ago
TAK
XOMA
Leerink says Takeda results signal positive readthrough for Alumis
PremiumThe Fly
Leerink says Takeda results signal positive readthrough for Alumis
1M ago
TAK
ALMS
Alumis price target raised to $20 from $14 at H.C. Wainwright
PremiumThe Fly
Alumis price target raised to $20 from $14 at H.C. Wainwright
1M ago
TAK
ALMS
Takeda announces zasocitinib studies met primary, secondary endpoints
PremiumThe Fly
Takeda announces zasocitinib studies met primary, secondary endpoints
1M ago
TAK
Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide
PremiumThe Fly
Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide
2M ago
TAK
PTGX
Takeda Advances Late-Stage Pipeline with Positive Phase 3 Data
PremiumCompany AnnouncementsTakeda Advances Late-Stage Pipeline with Positive Phase 3 Data
2M ago
6K
TAK
FDA investigating death following Adzynma treatment
Premium
The Fly
FDA investigating death following Adzynma treatment
2M ago
TAK
Takeda Pharmaceutical: Strategic Growth and Favorable Positioning Drive Buy Rating
Premium
Ratings
Takeda Pharmaceutical: Strategic Growth and Favorable Positioning Drive Buy Rating
2M ago
TAK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >